Aging-Focused BioAge Posts Q2 2025 Results: Advances Metabolic Pipeline and Expands Longevity Data Platform
BioAge Labs reported second-quarter 2025 results alongside updates on its metabolic disease pipeline and human aging data platform. The company is advancing its oral NLRP3 inhibitor toward Phase 1 testing in 2025, expanding its APJ agonist portfolio, and initiating large-scale molecular profiling through the HUNT Biobank. The update follows earlier developments including a multi-year Novartis collaboration worth up to $530 million.
Key Points
- NLRP3 inhibitor BGE-102: In May 2025, BioAge completed IND-enabling studies for BGE-102, an orally available, brain-penetrant NLRP3 inhibitor initially aimed at obesity. In preclinical models, BGE-102 produced significant weight loss both as monotherapy and in combination with the GLP-1 receptor agonist semaglutide. A Phase 1 SAD/MAD clinical trial is planned for 2H 2025, with initial single ascending dose data expected by year-end.
- APJ agonist expansion: Option agreement with JiKang Therapeutics for a nanobody with ≥10× potency over apelin; under the agreement, the nanobody will be advanced to the start of IND-enabling studies, after which BioAge holds an option for global rights across all indications. In May 2025, BioAge also filed a U.S. provisional patent for novel picomolar-potency oral APJ agonists with high solubility and stability.
- Discovery platform growth: Collaboration with Age Labs to profile 17,000+ samples from Norway’s HUNT Biobank, generating millions of molecular measurements with exclusive drug discovery rights.
- Strategic partnerships: Ongoing Novartis collaboration (December 2024) to identify drug targets at the intersection of aging biology and exercise physiology, and Lilly ExploR&D agreement (January 2025) for antibody development in metabolic aging.
- Financials: Q2 R&D expenses $19.8M (up from $10.5M in Q2 2024,partially offset by a $1.7M reduction in azelaprag-related spending following the program’s termination in January 2025), G&A expenses $7.3M (up from $4.8M), net loss $21.6M. Cash position $313.4M as of June 30, 2025, projected runway through 2029.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies that target the biology of aging to treat obesity and other metabolic diseases. The company’s computational discovery platform combines decades of longitudinal human longevity data with proprietary multi-omics datasets from large cohorts to identify molecular pathways that influence lifespan and healthspan.
Using AI-driven analysis and preclinical validation, BioAge advances drug candidates designed to modulate these pathways for specific age-related diseases. Current programs include an oral, brain-penetrant NLRP3 inhibitor and multiple APJ agonists in development for obesity. BioAge is backed by investors including Andreessen Horowitz, AME Cloud Ventures, PEAR Ventures, Felicis Ventures, and Caffeinated Capital.
Topic: Biotech Ventures
